Following the recent interview of Dr. Furman (by the way, my CLL expert) with Brian on PatientPower in which he speculated on using ABT-199 after an initial treatment wtih Ibrutinib, here is an article from Medscape yesterday on ABT-199. An excerpt:
"Despite heavy previous therapy, the response rate was still 70% to 80%, and that's independent of 17p status, which is a very remarkable observation...with these very exciting new agents targeting CLL biology, we really are entering an era where chemotherapy as the mainstay of treatment can be overcome...the striking thing about ABT-199 is that, compared with [the CLL drug] ibrutinib, it leads to much more rapid cell destruction, even in high-risk CLL patients."
[Note: will need registration to Medscape which is free]
Photo: a sunset two years ago over the Atlantic Ocean from Tarifa, at the southern tip of Spain, separating the Mediterranean from the Atlantic. The sunset represents the death of chemotherapy for all of us CLL patients.